Trump eager to sign bill rolling back Dodd-Frank

Leslie Hanson
May 24, 2018

The House of Representatives voted 258-159 to approve the measure, sending it to the president to sign into law. But there's no sign that Senate Democrats - whose votes are needed for passage - will get on board. The vote was 250 to 169.

The measure, championed by Sen. Ron Johnson, R-Wis., also provides some legal protections for pharmaceutical makers, doctors or others involved in providing the treatment. Many physicians, including Richard Klein, the former director of the FDA's Patient Liaison Program, have told our sister publication MD Magazine that they are in support of the incurably ill having access to unapproved therapies.

The FDA would be largely left out of the equation under the new legislation and would not oversee the right-to-try process.

The legislation also requires CN and CP Rail to develop a plan to move the upcoming year's crop.

"We also believe that patients with terminal conditions should have access to experimental treatments that could potentially save their lives".

Patients would be eligible for right-to-try if they had a "life-threatening illness" and had exhausted all available treatment options. The medication itself must have completed early-stage safety testing, called Phase 1 trials, and be in active development with the goal of FDA approval.

Currently, right-to-try laws exist in 40 states, with only Alaska, Delaware, Hawaii, Kansas, Massachusetts, New Jersey, New Mexico, New York, Rhode Island, and Vermont, excluded.

The issue has been more challenging for FDA Commissioner Scott Gottlieb.


The win on the banking bill adds to Trump's marquee business-friendly legislative achievement, the sweeping tax bill enacted late a year ago that deeply cut taxes for corporations and wealthy individuals and offered more modest reductions for most ordinary Americans.

During the House floor debate, Rep. But if two - certainly if three fail, that would be a problem.

But House Energy & Commerce Committee Ranking Member Frank Pallone, D-N.J., slammed the Senate version on the floor, pointing to Gottlieb's October testimony before the committee and FDA's expanded access program as evidence that the bill is risky and unnecessary.

Friends of Cancer Research and a long list of medical research organizations and professional societies strongly objected the bill. So he says Republicans have used all the political gunpowder they had in this one bill. They provide more than half of small business loans and over 80 percent of agricultural loans.

ARNOLD: But Frank says he actually supports parts of the bill.

Ahead of the House vote, House Democratic leader Nancy Pelosi of California and California's Rep. Maxine Waters, the top Democrat on the House Financial Services Committee, urged their colleagues not to vote in favor of the bill. In April, Americans for Prosperity, which is backed by the Koch brothers, launched a national advertising campaign calling on Congress to pass the bill. "It is time for the House to do what Senate Democrats won't and send a right-to-try bill to the President's desk, bringing hope to terminally-ill patients across the country", Walden said in a statement upon the vote's announcement. "The Senate's bill would allow unproven therapies to be given to patients without FDA notification for up to a full year and would not establish any standards for informed consent".

They said the measure would give people diagnosed with life-threatening conditions and who've exhausted treatment options access to potentially unsafe or futile unproven drugs.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER